Cobalis Corp. is an Irvine, CA-based OTC allergy medicine developer whose core product is the revolutionary PreHistin™, which is the world’s first PreHistamine™. Cobalis acquired the US patent for cyanocobalamin as an Immunoglobulin E (IgE) delimiter in 1992, and began work on this amazing new medicine, which actually prevents histamine release by the immune system.
Recognized as safe by the FDA and by leading regulatory authorities worldwide, cyanocobalamin is an analogue of cobalamin, a type of cobalt-containing complex molecule needed for all mammalian cells which are in the Vitamin B12 class, and – with no known contradictions or upper-dosage limit – it means that PreHistin is incredibly safe and effective.
Formulated as a lozenge, PreHistin can be taken anywhere, at any time, making it easy to use, thus getting rid of the need to take powerful antihistamines and other allergy drugs to fight the oppressive symptoms allergy sufferers the world over know and despise. Additionally, with multiple formulations and additional indications and applications, PreHistin stands to become a solution for a wide variety of allergic diseases.
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment